\n<\/p>\n
VCs who have backed OpenEvidence are apparently not worried about new health information products from OpenAI and Anthropic<\/a>.\u00a0<\/p>\n On Wednesday, the startup announced<\/a> that it raised an additional $250 million in Series D funding at a $12 billion valuation, co-led by Thrive Capital and DST.\u00a0\u00a0<\/p>\n That\u2019s double the valuation from its last raise in October: $200 million at $6 billion, led by GV<\/a>. It has now raised a total of $700 million, the company says, from backers including Sequoia, Nvidia, Kleiner Perkins, Blackstone, Bond, Craft Ventures, Mayo Clinic, and others.\u00a0<\/p>\n OpenEvidence is an AI-powered medical information platform, similar to what WebMD was for the previous internet generation, but it\u2019s geared toward doctors. This puts it somewhat more in competition with Anthropic\u2019s Claude for Healthcare<\/a>, which is intended for patients, payers, and providers, whereas ChatGPT\u2019s new health product<\/a> is aimed more at consumers.<\/p>\n The company says that the free, ad-supported platform served 18 million clinical consultations from verified healthcare professionals in the U.S. in December alone. That compares to about 3 million searches per month a year ago.\u00a0It also said that it had surpassed $100 million in revenue.\u00a0<\/p>\n<\/div>\n